Atopic dermatitis/eczema
Improved outcomes with dupilumab versus tralokinumab, real-world data reveals
Long-term benefits of dupilumab in paediatric severe atopic dermatitis revealed
Delgocitinib cream boosts quality of life in chronic hand eczema, dual analysis shows
Atopic eczema linked to significantly higher risk of suicidal thoughts
Lebrikizumab plus TCS shows sustained disease control in refractory atopic dermatitis
Unmet need in chronic hand eczema highlighted in real-world review
Eczema symptoms unaffected by bathing frequency, study finds
Unlocking multinational real-world research in atopic dermatitis
Guideline adherence for atopic dermatitis prescribing: a follow-on audit
Dupilumab discontinuation and atopic dermatitis flare-up risk
Impact of dupilumab on children's quality of life and treatment-related anxiety identified
Subpopulations of children with atopic dermatitis linked to cognitive impairment
Gut microbiome and allergies in newborns positively impacted by Covid lockdowns
Delgocitinib cream shows promise in moderate-to-severe chronic hand eczema
Skin diseases have underestimated effect on quality of life, according to pan-European study